News from oncopeptides ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

28 Jun, 2019, 07:26 BST Oncopeptides has Completed a Directed Share Issue of Approximately SEK 727 Million

Not For Publication, Distribution or Release, Directly or Indirectly, in or into the United States of America, Canada, Israel, Japan, South Africa or ...


27 Jun, 2019, 16:52 BST Oncopeptides Intends to Make a Directed Share issue

Oncopeptides AB (publ) ("Oncopeptides" or the "Company") (Nasdaq Stockholm: ONCO) today announces its intention to execute a directed share issue to...


16 Jun, 2019, 15:09 BST New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial....


14 Jun, 2019, 09:20 BST New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

Oncopeptides AB (Nasdaq Stockholm: ONCO), announced today new data presented at the 24th Congress of the European Hematology Association (EHA) in...


13 Jun, 2019, 08:12 BST Oncopeptides Will Host a Webcast on Monday, 17 June at 09:00 (CET) to Review and Update Presentations From European Hematology (EHA) Meeting

Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will make a review and update on the presented data from the European...


03 Jun, 2019, 14:22 BST New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting

Oncopeptides AB (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat...


28 May, 2019, 09:17 BST Oncopeptides to Present at the Jefferies Healthcare Conference in New York on June 7th at 11.30am EST

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will attend the Jefferies annual Healthcare Conference in New York between June...


21 May, 2019, 15:31 BST Bulletin From The Annual General Meeting in Oncopeptides Ab (publ)

Oncopeptides AB (publ)'s (ONCO) Annual General Meeting 2019 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the...


21 May, 2019, 07:23 BST Oncopeptides AB: INTERIM REPORT Q1 2019

"The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides." Financial overview January 1 – March 31, 2019...


16 May, 2019, 14:18 BST Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that a total of four abstracts have been accepted for presentation at the 24th Congress of...


16 May, 2019, 00:10 BST Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic...


24 Apr, 2019, 06:48 BST Oncopeptides Provides New Guidance on the Patient Recruitment in the OCEAN Study and a Clinical Program Update in a Webcast at 10:00 (CET)

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the company will provide an update on patient recruitment in the ongoing phase 3 study...


16 Apr, 2019, 10:32 BST Annual General Meeting in Oncopeptides AB (publ)

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, ("Oncopeptides" or the...


11 Apr, 2019, 09:49 BST Oncopeptides AB: Updated Financial Calendar

Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has updated its financial calendar, the interim report for Q2 2019 have been moved...


10 Apr, 2019, 07:33 BST Additional Patent Protection for Melflufen Granted in the US Until 2033

Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the US patent and trademark office has issued a notice that they intend to grant...


28 Feb, 2019, 00:12 GMT Data From Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting

Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that data from its Phase II HORIZON study and Phase I/II ANCHOR study evaluating the...


25 Feb, 2019, 13:17 GMT Oncopeptides to present at the Cowen and Company Annual Healthcare Conference on Monday 11th March at 4:10 pm Eastern Standard Time

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Jakob Lindberg, CEO at Oncopeptides, will present the company at Cowen and Company 39th ...


22 Feb, 2019, 07:32 GMT Oncopeptides AB: Year-end Report 2018

Summary of Q4 Financial overview October 1 – December 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 111.4 M (loss: 66.2) ...


18 Feb, 2019, 09:49 GMT Oncopeptides Will Host a Webcast in Conjunction With its Year-end Report 2018 on 22 February at 14.00 (CET)

Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Company will release its Year-end Report on 22 February at 8:00 am CET. The report...


05 Dec, 2018, 10:45 GMT Program for Oncopeptides Capital Markets Day December 14th, 2018

Oncopeptides AB (Nasdaq Stockholm: ONCO) have previously announced that they will host a Capital Markets Day in New York. The program is now...


03 Dec, 2018, 16:29 GMT Interim Data from the Ongoing HORIZON Trial with Melflufen Presented in an Oral Presentation at the 60th American Society of Hematology Meeting

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Professor Paul G. Richardson presented updated interim data with melflufen (Ygalo®)...


02 Dec, 2018, 14:14 GMT Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting

Overall conclusions The combinations of melflufen and dexamethasone (dex) with either bortezomib or daratumumab in relapsed-refractory multiple...


01 Nov, 2018, 13:43 GMT Oncopeptides to Present Updated Data From the Two Ongoing Trials ANCHOR and HORIZON in Patients with RRMM at ASH in December 2018

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the abstracts for the 60th American Society of Hematology (ASH) meeting (December...


15 Aug, 2016, 15:00 BST Oncopeptides Welcomes New Board Member - Luigi Costa

Oncopeptides AB, a clinical stage company developing an effective, peptidase targeted therapy for the treatment of multiple myeloma announces the...


20 Aug, 2013, 14:00 BST Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients

Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study...